Assessing the aneurysm occlusion efficacy of a shear-thinning biomaterial in a 3D-printed model
- PMID: 35397405
- PMCID: PMC9060636
- DOI: 10.1016/j.jmbbm.2022.105156
Assessing the aneurysm occlusion efficacy of a shear-thinning biomaterial in a 3D-printed model
Abstract
Metallic coil embolization is a common method for the endovascular treatment of visceral artery aneurysms (VAA) and visceral artery pseudoaneurysms (VAPA); however, this treatment is suboptimal due to the high cost of coils, incomplete volume occlusion, poor reendothelialization, aneurysm puncture, and coil migration. Several alternative treatment strategies are available, including stent flow diverters, glue embolics, gelfoam slurries, and vascular mesh plugs-each of which have their own disadvantages. Here, we investigated the in vitro capability of a shear-thinning biomaterial (STB), a nanocomposite hydrogel composed of gelatin and silicate nanoplatelets, for the minimally-invasive occlusion of simple necked aneurysm models. We demonstrated the injectability of STB through various clinical catheters, engineered an in vitro testing apparatus to independently manipulate aneurysm neck diameter, fluid flow rate, and flow waveform, and tested the stability of STB within the models under various conditions. Our experiments show that STB is able to withstand at least 1.89 Pa of wall shear stress, as estimated by computational fluid dynamics. STB is also able to withstand up to 10 mL s-1 pulsatile flow with a waveform mimicking blood flow in the human femoral artery and tolerate greater pressure changes than those in the human aorta. We ultimately found that our in vitro system was limited by supraphysiologic pressure changes caused by aneurysm models with low compliance.
Keywords: Catheters; Hydrogels; Minimally invasive; Pseudoaneurysms; Shear-thinning biomaterials; Silicate nanoplatelets; Visceral artery aneurysms.
Copyright © 2022 Elsevier Ltd. All rights reserved.
Conflict of interest statement
Conflict of Interest
A. K. is a co-founder of a start‐up company, Obsidio, Inc., which is based on shear‐thinning embolic materials.
Declaration of interests
The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
Ali Khademhosseini reports financial support was provided by National Institutes of Health. Ali Khademhosseini reports a relationship with Obsidio, Inc that includes: board membership and equity or stocks. Ali Khademhosseini has patent Shear-thinning compositions as an intravascular embolic agent issued to Obsidio, Inc.
Figures





Similar articles
-
A Cohesive Shear-Thinning Biomaterial for Catheter-Based Minimally Invasive Therapeutics.ACS Appl Mater Interfaces. 2022 Sep 28;14(38):42852-42863. doi: 10.1021/acsami.2c08799. Epub 2022 Sep 19. ACS Appl Mater Interfaces. 2022. PMID: 36121372
-
An injectable shear-thinning biomaterial for endovascular embolization.Sci Transl Med. 2016 Nov 16;8(365):365ra156. doi: 10.1126/scitranslmed.aah5533. Sci Transl Med. 2016. PMID: 27856795
-
The endovascular management of visceral artery aneurysms and pseudoaneurysms.J Vasc Surg. 2007 Feb;45(2):276-83; discussion 283. doi: 10.1016/j.jvs.2006.10.049. J Vasc Surg. 2007. PMID: 17264002
-
Flow-diverting stents for the treatment of arterial aneurysms.J Vasc Surg. 2012 Sep;56(3):839-46. doi: 10.1016/j.jvs.2012.04.020. Epub 2012 Jul 26. J Vasc Surg. 2012. PMID: 22840737 Review.
-
Injectable hydrogels for vascular embolization and cell delivery: The potential for advances in cerebral aneurysm treatment.Biomaterials. 2021 Oct;277:121109. doi: 10.1016/j.biomaterials.2021.121109. Epub 2021 Aug 31. Biomaterials. 2021. PMID: 34530233 Review.
Cited by
-
Biomimetic Glycosaminoglycan-Analog Hydrogel for Improved Embolization of Aneurysms: Environment-Selective Swelling.Adv Healthc Mater. 2025 Jul;14(17):e2404506. doi: 10.1002/adhm.202404506. Epub 2025 Apr 7. Adv Healthc Mater. 2025. PMID: 40192445 Free PMC article.